CAZZANIGA MARINA ELENA

Ardakani, K., Passarella, G., Lania, A., Clementi, T., Fanti, A., Pepe, F., et al. (2026). Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review. CURRENT ONCOLOGY, 33(1) [10.3390/curroncol33010028]. Dettaglio

Cazzaniga, M., Cogliati, V., Rossi, E., Paris, I., Borella, F., Moretti, G., et al. (2026). Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study. ESMO REAL WORLD DATA AND DIGITAL ONCOLOGY, 11(March 2026) [10.1016/j.esmorw.2025.100665]. Dettaglio

Cazzaniga, M., Pepe, F., Rossi, E., Coltelli, L., Beano, A., Valerio, M., et al. (2025). A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial. CLINICAL BREAST CANCER, 25(6), 560-565 [10.1016/j.clbc.2025.05.003]. Dettaglio

Ardakani, K., Pepe, F., Capici, S., Clementi, T., Cazzaniga, M. (2025). Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC). CURRENT ONCOLOGY, 32(7) [10.3390/curroncol32070387]. Dettaglio

Cazzaniga, M., Pronzato, P., Amoroso, D., Arpino, G., Atzori, F., Beano, A., et al. (2025). Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA Study. CANCERS, 17(10) [10.3390/cancers17101715]. Dettaglio